Figure 2.
NK cells treated with NKTR-255 are characterized by increased expression of stimulatory receptors and activation markers. (A) NK cells purified from patients with MM were continuously cultured with NKTR-255 1 μg/mL for up to 7 days and the expression pattern of indicated surface markers was tracked by flow cytometry at different time points. Graphics show the fold-change of MFI compared with the MFI at day 0 (before treatment with NKTR-255) for each time point. (B-C) PBMCs were collected from patients with MM samples and cultured with and without NKTR255 or rhIL-15. After 5 days, PBMCs were stained with CD3 and CD56 antibodies to gate NK cell population as well as with indicated surface proteins. The expression profile of these markers was measured by flow cytometry. Representative histograms of the isotype control and the 4 culture conditions are shown (B). Fold change increase over isotype control in untreated and treated samples is shown in the graph (C). (D) PBMCs from patients with MM with progressive disease (n = 3) and complete response (n = 6) were treated with 1 μg/mL of NKTR-255 or 100 ng/ml of rh-IL15 for 5 days. PBMCs were then stained with CD3 and CD56 antibodies to gate NK cell population and NKG2D. Results are expressed as mean ± standard deviation of fold-change in absolute count after 5 days. (E) NK cells purified from patients with MM were continuously cultured with NKTR-255 1 μg/mL for up to 7 days and the expression pattern of indicated surface markers was tracked by flow cytometry at different time points. Graphics show the fold-change of MFI compared with the MFI at day 0 (before treatment with NKTR-255) for each time point. (F) PBMCs were collected from peripheral blood of patients with MM and culture with and without NKTR255 or rhIL-15. After 5 days, PBMCs were stained with CD3 and CD56 antibodies, to gate NK cell population, as well as with NKG2A antibody or isotype control. Representative histograms of the isotype control and the 4 culture conditions are shown in the graph. ∗P < .05. CR, complete response; MFI, median fluorescence intensity; MM, multiple myeloma; ns, not significant; NK, natural killer; PBMCs, peripheral blood mononuclear cells; Progr, progression; SD, standard deviation.

NK cells treated with NKTR-255 are characterized by increased expression of stimulatory receptors and activation markers. (A) NK cells purified from patients with MM were continuously cultured with NKTR-255 1 μg/mL for up to 7 days and the expression pattern of indicated surface markers was tracked by flow cytometry at different time points. Graphics show the fold-change of MFI compared with the MFI at day 0 (before treatment with NKTR-255) for each time point. (B-C) PBMCs were collected from patients with MM samples and cultured with and without NKTR255 or rhIL-15. After 5 days, PBMCs were stained with CD3 and CD56 antibodies to gate NK cell population as well as with indicated surface proteins. The expression profile of these markers was measured by flow cytometry. Representative histograms of the isotype control and the 4 culture conditions are shown (B). Fold change increase over isotype control in untreated and treated samples is shown in the graph (C). (D) PBMCs from patients with MM with progressive disease (n = 3) and complete response (n = 6) were treated with 1 μg/mL of NKTR-255 or 100 ng/ml of rh-IL15 for 5 days. PBMCs were then stained with CD3 and CD56 antibodies to gate NK cell population and NKG2D. Results are expressed as mean ± standard deviation of fold-change in absolute count after 5 days. (E) NK cells purified from patients with MM were continuously cultured with NKTR-255 1 μg/mL for up to 7 days and the expression pattern of indicated surface markers was tracked by flow cytometry at different time points. Graphics show the fold-change of MFI compared with the MFI at day 0 (before treatment with NKTR-255) for each time point. (F) PBMCs were collected from peripheral blood of patients with MM and culture with and without NKTR255 or rhIL-15. After 5 days, PBMCs were stained with CD3 and CD56 antibodies, to gate NK cell population, as well as with NKG2A antibody or isotype control. Representative histograms of the isotype control and the 4 culture conditions are shown in the graph. ∗P < .05. CR, complete response; MFI, median fluorescence intensity; MM, multiple myeloma; ns, not significant; NK, natural killer; PBMCs, peripheral blood mononuclear cells; Progr, progression; SD, standard deviation.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal